ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2993 • 2017 ACR/ARHP Annual Meeting

    Knee Joint Sounds: A Non-Invasive Modality for Classifying Knee Joint Health in Juvenile Idiopathic Arthritis

    Daniel Whittingslow1, Beren Semiz2, Lori Ponder3, Patricia Vega-Fernandez4, Omer Inan5 and Sampath Prahalad6, 1Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, 2Electrical and Computer Engineering, Georgia Institute of Technology, Atlanta, GA, 3Emory University, Atlanta, GA, 4Pediatrics, Emory University School of Medicine, Atlanta, GA, 5Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, 6Pediatrics, Emory Children's Center, Atlanta, GA

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common, chronic, childhood rheumatic disease and an important cause of disability. It is characterized by persistent inflammation…
  • Abstract Number: 2994 • 2017 ACR/ARHP Annual Meeting

    Improving Outcomes Using a Treat to Target Approach and Clinical Decision Support in Polyarticular Juvenile Idiopathic Arthritis

    Lisa Buckley1, Eileen Ware2, Genna Kreher2, Lisa Wiater1, Jay Mehta1 and Jon (Sandy) Burnham1, 1Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, 2Office of Clinical Quality Improvement, Children's Hospital of Philadelphia, Philadelphia, PA

    Background/Purpose:   Polyarticular juvenile idiopathic arthritis (Poly-JIA) causes pain, functional disability, and joint damage.  Variation in Poly-JIA clinical assessment and treatment likely has a negative…
  • Abstract Number: 2995 • 2017 ACR/ARHP Annual Meeting

    Pathogens in the Inflammatory Process of Periodontal Disease and Juvenile Idiopathic Arthritis

    Nancy Delnay1, Neil McNinch2 and Mary Toth3, 1Rheumatology, Akron Children's Hospital, Akron, OH, 2Rebecca Considine Research, Akron Children's Hospital, Akron, OH, 3Rheumatology, Children's Hospital Medical Center, Akron, OH

    Background/Purpose: Juvenile idiopathic arthritis (JIA) and periodontal disease (PD) are both diseases of inflammation that can result in bone loss when the inflammatory process is…
  • Abstract Number: 2996 • 2017 ACR/ARHP Annual Meeting

    Resilience and Transition Readiness in Pediatric SLE Patients

    Jamie Lai1, Lorene Nelson2, Imelda Balboni1, Tzielan Lee1 and Joyce Hsu1, 1Pediatric Rheumatology, Stanford University, Palo Alto, CA, 2Health Research and Policy - Epidemiology, Stanford University, Palo Alto, CA

    Background/Purpose: Childhood onset systemic lupus erythematosus (SLE) is a chronic autoimmune condition with high morbidity that requires long-lasting care through adulthood. Transition from pediatric to…
  • Abstract Number: 2997 • 2017 ACR/ARHP Annual Meeting

    Patient and Family Reported Psychosocial Areas of Concern within Pediatric Rheumatology: Quality Improvement Data and Implications for Practice

    Nicole Tennermann and Melissa Hazen, Rheumatology, Boston Children's Hospital, Boston, MA

    Background/Purpose: Psychosocial factors greatly impact the subjective disease experience and outcomes of children with rheumatic conditions. Attention to the psychosocial aspects of patients’ needs is…
  • Abstract Number: 135 • 2017 Pediatric Rheumatology Symposium

    Epigenetic Profiling Of Juvenile Idiopathic Arthritis (JIA) Synovial Fluid Monocytes Points Towards a Role For Monocytes In Bone Damage

    Janneke Peeters1, Arjan Boltjes2,3, Stephin Vervoort4, Paul Coffer1, Bas Vastert2,5, Femke van Wijk2,3, Michal Mokry3, Teun de Vries6,7 and Jorg van Loosdregt3, 1Center for Molecular Medicine and Regenerative Medicine Center Utrecht, University Medical Center Utrecht, Utrecht, Netherlands, 2Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3Division of Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands, 4Peter MacCallum Cancer Centre, Melbourne, Australia, 5Division of Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, 6Department of Oral Cell Biology and Functional Anatomy, Academic Centre for Dentistry Amsterdam, Amsterdam, Netherlands, 7Department of Periodontology, Academic Centre for Dentistry Amsterdam, Amsterdam, Netherlands

    Background/Purpose:  Juvenile Idiopathic Arthritis (JIA) is a multifactorial autoimmune disease characterized by the accumulation of various immune cells, including monocytes, in the joint synovial fluid…
  • Abstract Number: 49 • 2017 Pediatric Rheumatology Symposium

    Perceptions of Methotrexate Intolerance in School-aged Children With Juvenile Idiopathic Arthritis

    Charlene Hopper1, Sarah Khan2, Jacqueline Mancini2 and Janet Rennick3,4, 1Rheumatology, Montreal Children's Hospital McGill University Health Centre, Montreal, QC, Canada, 2Ingram School of Nursing, McGill University, Montreal, QC, Canada, 3Nursing, Montreal Children's Hospital McGill University Health Centre, Montreal, QC, Canada, 4Ingram School of Nursing and Department of Pediatrics, McGill University, Montreal, QC, Canada

    Background/Purpose:  Methotrexate (MTX) remains an effective and commonly used disease modifying anti-rheumatic drug (DMARD) for the treatment of Juvenile Idiopathic Arthritis (JIA). Approximately half of the children taking MTX will…
  • Abstract Number: 11 • 2017 Pediatric Rheumatology Symposium

    Safety of Adalimumab ± Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA): STRIVE Registry

    Hermine Brunner1, Nicolino Ruperto2, Kabita Nanda3, Mary Toth4, Ivan Foeldvari5, John F. Bohnsack6, Diana Milojevic7, C. Egla Rabinovich8, Daniel Kingsbury9, Katherine Marzan10, Pierre Quartier11, Kirsten Minden12, Elizabeth Chalom13, Gerd Horneff14, Rolf M. Kuester15, Jason A Dare16, Mareike Bereswill17, Jasmina Kalabic17, Hartmut Kupper18, Daniel J. Lovell19 and Alberto Martini2, 1Rheumatology, PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2PRINTO-IRCCS Gaslini, Genova, Italy, 3Seattle Childrens Hospital, Bayside, NY, 4Rheumatology, Akron Children's Hospital, Akron, OH, 5Kinder- und Jugenrheumatologie, Hamburger Zentrum Kinder-und Jugendrheumatologie, Hamburg, Germany, 6Division of Allergy, Immunology and Pediatric Rheumatology, University of Utah, Salt Lake City, UT, 7Tufts Medical Center, Boston, MA, 8Duke University Medical Center, Durham, NJ, 9Pediatric Rheumatology, Randall Children's Hospital at Legacy Emanuel, Portland, OR, 10Children's Hospital Los Angeles, Los Angeles, CA, 11Hopital Necker-Enfants Malades, Paris, France, 12Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, 13PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 14Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, 15Orthopädiezentrum Altona, Hamburg, Germany, 16Arkansas Children’s Hospital, Little Rock, AR, 17AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 18Clinical Oncology/Immunology, AbbVie Deutschland GmbH & Co. KG, Ludnigshafen, Germany, 19Rheumatology MLC 4010, PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: JIA is the most common chronic inflammatory rheumatic disease of childhood. Due to their known safety and efficacy, TNF inhibitors are used for long-term…
  • Abstract Number: 56 • 2017 Pediatric Rheumatology Symposium

    Prevalence of Serum 14-3-3η in Juvenile Idiopathic Arthritis

    Iris Reyhan1, Olga S. Zhukov2, Robert J. Lagier3, Robert Bridgforth4, Gary J Williams5, Joanna M. Popov2, Stanley J. Naides2 and Andreas Reiff6, 1Rheumatology, Children's Hospital of Los Angeles, Los Angeles, CA, 2Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, 3Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, 4quest diagnostics Nichols Institue, clemente, CA, 5Nicolas Institue, Quest Diagnostics, San Juan Capistrano, CA, 6Children’s Hospital of Los Angeles, Los Angeles, CA

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease. Currently, diagnosis is based on clinical assessment defined by the International League of…
  • Abstract Number: 30 • 2017 Pediatric Rheumatology Symposium

    Cross-sectional Analysis of Depression and Medication Non-Adherence in Childhood-onset Systemic Lupus Erythematosus

    Alaina M. Davis1, T. Brent Graham1, Yuwei Zhu2 and Melissa L. McPheeters3, 1Pediatric Rheumatology, Monroe Carell Junior Children's Hospital at Vanderbilt, Division of Pediatric Rheumatology, Nashville, TN, 2Biostatistics, Vanderbilt University, Department of Biostatistics, Nashville, TN, 3Health Policy, Vanderbilt University Medical Center, Department of Health Policy, Nashville, TN

    Background/Purpose: The objectives of this study were to estimate prevalence of depression and medication non-adherence, describe demographic and disease characteristics associated with depression and medication…
  • Abstract Number: 129 • 2017 Pediatric Rheumatology Symposium

    Cell-bound Complement Activation Products Correlate with Disease Activity in Childhood-onset Systemic Lupus Erythematosus

    Joyce Hui-Yuen1, Derren Barken2, John Conklin3, Tyler O'Malley4, Andrew Eichenfield5, Amy Starr6, Lisa F. Imundo7, Thierry Dervieux4 and Anca Askanase8, 1Cohen Children's Medical Center of New York, Lake Success, NY, 2Exagen Diagnostics, Vista, CA, 31261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, 4Research and Development, Exagen Diagnostics, Vista, CA, 5Columbia University Medical Center, New York, NY, 6Pediatric Rheumatology, Columbia University Medical Center, New York, NY, 7Pediatrics, Columbia University Medical Center, New York, NY, 8Rheumatology, Columbia University Medical Center, New York, NY

    Background/Purpose: Elevated levels of cell-bound complement activation products (C4d deposition on erythrocytes [EC4d] and B lymphocytes [BC4d], CB-CAPs) have been demonstrated to be sensitive and…
  • Abstract Number: 63 • 2017 Pediatric Rheumatology Symposium

    Performance of Disease Activity Measures in Pediatric Patients With Enthesitis-related Arthritis

    Rubén Burgos-Vargas1, Gerd Horneff2, Shirley M.L. Tse3, Pierre Quartier4, Kristina Unnebrink5 and Jaclyn K. Anderson6, 1Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, 2Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, 3The Hospital for Sick Children, Toronto, ON, Canada, 4Hopital Necker-Enfants Malades, Paris, France, 5AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 6AbbVie Inc., North Chicago, IL

    Background/Purpose: Enthesitis-related arthritis (ERA) is a category of juvenile idiopathic arthritis (JIA), with clinical features similar to those of adult spondyloarthritis (SpA). An unmet ERA…
  • Abstract Number: 82 • 2017 Pediatric Rheumatology Symposium

    Disease Burden and Social Impact of Chronic Nonbacterial Osteomyelitis on Affected Children and Young Adults

    Melissa Oliver1, Tzielan Lee2, Bonnie Halpern-Felsher3, Elizabeth Murray4, Rebecca Gholson5 and Yongdong Zhao6, 1Pediatric Rheumatology, Stanford University, Department of Pediatric Rheumatology, Palo Alto, CA, 2Stanford University, Department of Pediatric Rheumatology, Palo Alto, CA, 3Pediatrics, Adolescent Medicine, Stanford University, Department of Pediatrics, Adolescent Medicine, Palo Alto, CA, 4CRMO Facebook Support Group, Seattle, WA, 5CRMO Facebook Support Group, Asheville, NC, 6Seattle Children's Hospital, Department of Pediatric Rheumatology, University of Washington, Seattle, WA

    Background/Purpose: Chronic Nonbacterial Osteomyelitis (CNO) is a rare autoinflammatory bone disorder that can result in bone destruction, persistent bone pain, growth disturbances and pathological fractures.…
  • Abstract Number: 110 • 2017 Pediatric Rheumatology Symposium

    Risk Factors for Poor Health-Related Quality of Life in Children with Inflammatory Brain Diseases

    Elina Liu1, Anastasia Dropol2, Marinka Twilt2, Pascal Tyrrell3, Shehla Sheikh4, Susanne Benseler2 and The BrainWorks Investigator Network, 1Pediatric Rheumatology, Alberta Children's Hospital, Calgary, AB, Canada, 2Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, 3Medical Imaging, University of Toronto, Toronto, ON, Canada, 4Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: Inflammatory Brain diseases (IBrainD) are increasingly recognized causes of devastating neurological deficits in previously healthy children. Although the mortality has dramatically improved, disease and…
  • Abstract Number: 33 • 2017 Pediatric Rheumatology Symposium

    An extracellular ionic milieu renders human granulocytic S100A12 into a pro-inflammatory TLR4-binding alarmin

    Christoph Kessel1, Sabrina Fuehner1, Bastian Zimmermann2, Dirk Holzinger1, Helmut Wittkowski1, Claas Hinze1 and Dirk Foell1, 1Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany, 2Biaffin GmbH & Co KG, Kassel, Germany

    Background/Purpose:  Granulocytic S100A12 is a member of the calgranulin-subgroup within the S100 family of calcium-binding proteins. Similar to other S100 proteins S100A12 can bind divalent…
  • « Previous Page
  • 1
  • …
  • 1403
  • 1404
  • 1405
  • 1406
  • 1407
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology